Lactobacillus rhamnosus is a gram positive, lactic acid producing bacterium that is commonly found in the human gastrointestinal tract (1). This probiotic strain has gained increasing attention in recent years for its numerous health benefits. Clinical studies have shown that it has a multitude of therapeutic benefits, particularly in enhancing the immune system, preventing, and treating gastrointestinal infections and diarrhoea, preventing specific allergic symptoms, and providing protection against infections in the female reproductive system (2).
If you have a weakened immune system, please consult your health care practitioner before using this product.
Epigenetics probiotic Lactobacillus rhamnosus is produced in a vegan friendly and convenient delayed release capsule. Recommended daily dose is 1 serving per day taken after a meal, or as directed by a healthcare practitioner. This product is not intended to be used as an alternative to a varied diet.
Add a pot & scoop to your order to better store your probiotics and make dosing and mixing powders easier.
||Amount per serving
|Inulin (from Jerusalem artichoke)
||50 mg (5B CFU)
† Percent Daily Reference Intakes (RI) not established.
INGREDIENTS: Organic Jerusalem artichoke tuber extract (Helianthus tuberosus), Lactobacillus rhamnosus.
Suitable for vegans
One of the primary benefits of Lactobacillus rhamnosus is its ability to aid gut health. Research has shown that not only does Lactobacillus rhamnosus prevent the growth of bad bacteria but also promotes the growth of beneficial bacteria, such as Bacteroides, Clostridia, and bifidobacterial. Studies also suggest that Lactobacillus rhamnosus helps to increase the production of short-chain fatty acids, including acetate, propionate, and butyrate. These have several benefits such as protection against colon cancer, weight loss, and lower blood sugar levels (1).Bottom of Form
Recent research has shown that Lactobacillus rhamnosus can be found to be beneficial in protecting against antibiotic-related diarrhoea, which can result from the disruption of the microbiota due to antibiotics. In fact, studies have demonstrated that supplementing with a particular stain of Lactobacillus rhamnosus known as Lactobacillus rhamnosus GG can significantly reduce the risk of antibiotic-related diarrhoea. Taking a probiotic before and after antibiotic use can also help restore the healthy gut bacteria that are often killed by antibiotics. Furthermore, Lactobacillus rhamnosus has been shown to protect against other types of diarrhoea, such as travellers’ diarrhoea, acute watery diarrhoea, and acute gastroenteritis-related diarrhoea (1).
Lactobacillus rhamnosus may play a role in promoting vaginal and urinary tract health. Research suggests that Lactobacillus rhamnosus is a potent treatment for vaginal infections and protection against yeast overgrowth in women. Studies have shown that Lactobacillus rhamnosus can displace and prevent the adhesion of pathogens that can affect the intestinal and urogenital regions. It also inhibits the growth of harmful bacteria and yeast, including Candida albicans. Moreover, Lactobacillus rhamnosus has a robust acid production that can help kill viruses. It also prevents the formation of clumps or biofilms that can be challenging to eliminate using conventional drugs (2).
Likewise, Lactobacillus rhamnosus may help with respiratory illnesses and several studies have demonstrated the effectiveness of Lactobacillus rhamnosus in reducing the risk of respiratory tract infections (RTIs) and related symptoms in children and hospitalised patients. Fermented milk containing Lactobacillus rhamnosus was found to be efficient in reducing the risk of RTIs lasting longer than three days in hospitalised children. Preterm infants treated with Lactobacillus rhamnosus in capsules starting within one week after birth also had a significantly lower incidence of RTIs and rhinovirus-induced episodes in the first two months. Similarly, consuming Lactobacillus rhamnosus reduced the occurrence of respiratory illness in children attending day care centres and children who received Lactobacillus rhamnosus probiotics had fewer days with respiratory symptoms per month than the control group. In hospitalised patients capsulated Lactobacillus rhamnosus protected against ventilator-associated pneumonia caused by Gram-negative pathogens like Pseudomonas aeruginosa. In cystic fibrosis patients with Pseudomonas aeruginosa, long-term Lactobacillus rhamnosus significantly decreased the incidence of pulmonary exacerbations and increased body weight (3).
Finally, Lactobacillus rhamnosus has been found to be effective in preventing the development of eczema and atopic sensitisation in high-risk infants up to the age of 6 years. In children, the cumulative prevalence of eczema and rhino conjunctivitis was significantly reduced with the consumption of Lactobacillus rhamnosus. Moreover, this probiotic has been shown to decrease symptoms of atopic dermatitis in children aged 4-48 months after an 8-week treatment. In mice, the oral application of Lactobacillus rhamnosus was also found to prevent the development of atopic dermatitis by inhibiting the production of inflammatory cytokines (3).
Packaging: 15 g
Recommended daily dose, 1 serving taken last thing at night on a empty stomach. Put the powder into a glass, add 100 ml of water and stir until dissolved.
Serving size: 1g Servings per container: 15
Store in a refrigerator out of reach and sight of children. Once opened, consume within 6 months.